Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
- Smoking History and Overall Survival in Patients Receiving First-Line Pembrolizumab for Advanced NSCLC
- Addition of Bevacizumab to Erlotinib as First-Line Treatment for EGFR-Mutated Advanced Nonsquamous NSCLC
- Impact of Smoking Status on the Efficacy of EGFR-TKI Plus Angiogenesis Inhibitor Combination Therapy in Advanced NSCLC
Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLCLung Cancer 2022 Aug 01;170(xx)91-97, BD Qin, XD Jiao, Y Wang, Y Wu, Y Ling, K Liu, YS Zang
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.